It’s been more than 16 years since Doron Kochavi’s son Ari was diagnosed with cancer, yet the emotion it evokes makes it seem like just yesterday. Ari beat the odds despite an aggressive brain tumor and while he is now a 20-year-old young adult, it doesn’t take much for Doron to feel the pain and fear that overcame him when his little boy faced such grueling treatment and an uncertain future.

However anguished he may feel to recall Ari’s experience, Doron ultimately exudes pride and gratitude for what their team of doctors called his “miracle child.” Ari remains cancer-free today, Doron says, because his son took part in a clinical trial. “Ari is a living example of what it takes to survive cancer. He is alive today because of clinical trials.”

During his cancer treatment and continuing to this day, Ari’s courage, positive attitude and perseverance inspire everyone he meets. Surgery and subsequent treatment for the brain tumor affected Ari’s ability to ride a bike, so Doron rides a tandem with him, taking the seat in front to lead and keep the bike steady. But without Ari’s help pedaling, talking and laughing, Doron says, there would be no purpose for him to be alone on the bike. “As in life, Ari gives me the opportunity to see the road from a different perspective. My son has taught my wife Phyllis and I that, like cycling, the fight against cancer is truly a team effort.”

Ari’s survival and the stories of many other children affected by cancer will motivate Doron throughout his eight-day journey across the United States as a member of the Bristol-Myers Squibb Tour of Hope™ Team. Doron and Phyllis are not only grateful to those who participated in clinical trials before them, but are committed to sharing the message of research with future cancer survivors.

Ari’s cancer occurred many years ago, but it continues to shape his family’s life. Doron is delighted to speak of his son, who meets each day with optimism and hope despite the challenges he faces. “A new chapter is written every day and we take great pride in repeating it,” Doron says. “We must continue to speak in order to remind ourselves and others of the importance of clinical trials.”